Pharmacokinetics and metabolism of [14C]BMS-820836 in healthy male subjects

Completed

• Conditions: anxiety disorders; Depression; 10027946

• Registration Number: NL-OMON34571
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

healthy male subjects, up to moderate smoking
Age: 18-45 years
BMI: 18.0-30.0 kg/m2

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study or in case of donating more than 1 liter of blood in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Radiokinetics<br /><br>- Pharmacokinetics<br /><br>- Safety</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N.a.</p><br>